Achillion’s Milind Deshpande, New Haven Pharma’s Patrick Fourteau Win 2015 Entrepreneur of the Year Awards

2105-award-genericAt a ceremony on December 8 in New Haven CT, CURE, the Connecticut bioscience organization, presented the 2015 CURE Entrepreneur of the Year Award to Milind Deshpande of Achillion Pharmaceuticals and Patrick Fourteau of New Haven Pharmaceuticals, two biotechnology executives whose companies have developed promising new pharmaceutical products through the expert management of new approaches to drug development.

The CURE Entrepreneur of the Year Award was established by CURE and Shipman & Goodwin LLP in 2013 to acknowledge the importance of showcasing unique accomplishments of entrepreneurs in the Connecticut bioscience community.

The award presentations were made during the annual CURE Holiday Party, which has become an important networking event for Connecticut’s bioscience community, thanks to the generosity of its sponsors. This year’s sponsors included Shipman & Goodwin LLP, Winstanley Enterprises, Svigals + Partners, TEKsystems, Economic Development Corporation of New Haven, AON, Elm Street Ventures, Access A/V, Fortunato Construction Group, and Ware, Fressola, Maguire & Barber LLP.

In her introductory remarks, Dr. Susan Froshauer, president and CEO of CURE, said, “It is such a pleasure to honor these two Connecticut entrepreneurs. Under their leadership, their companies and employees are delivering new levels of excellence.”

Dormer Stephen, a partner at Shipman & Goodwin, said “Milind and Patrick exemplify the entrepreneurial spirit that is alive and well in the Connecticut bioscience community. We are proud to recognize and showcase their accomplishments.”


milindDr. Milind Deshpande is President & CEO of Achillion Pharmaceuticals, a publicly traded pharmaceutical company focused on discovery and development of small molecule therapeutics for high unmet need. Achillion applies expertise in biology and structure-guided design and a deep understanding of patient, clinician, and payer needs to develop innovative treatment solutions aimed at improving patients’ lives.

According to a colleague and scientist familar with his work, “Milind has inspired and led extraordinary examples of innovation in the antiviral arena, culminating in the establishment of a world-class portfolio of early to mid stage compounds targeting Hepatitis C virus. One of the company’s compounds, ACHN-3102, was developed from ‘white board’ to IND in 10 months. I am not aware of any other case study in recent history which not only accomplished that feat, but also resulted in the molecule emerging as the gold standard for the NS5a mechanism.”

Dr. Deshpande joined Achillion Pharmaceuticals in 2001 and previously was the President of R&D and Chief Scientific Officer there. During his tenure as the CSO, Achillion developed a robust portfolio for treatment of hepatitis C, culminating in an important worldwide license and collaboration agreement with Janssen Pharmaceuticals. Prior to joining Achillion, Milind headed the early discovery programs in Infectious Disease and Neuroscience at Bristol-Myers Squibb. Milind received his Ph.D. in Organic Chemistry from Ohio University. He was post-doctoral fellow and a faculty member of the Department of Medicine, Boston University School of Medicine.


fourteauPatrick Fourteau is President & CEO of New Haven Pharmaceuticals, a company that combines an evolutionary approach to drug development with state-of-the-art technology platforms. By applying contemporary metadata analysis to large volumes of medical information, the company is able to create new solutions and significant health benefits while leveraging knowledge gleaned from decades of clinical knowledge about highly regarded drugs.

According to an industry executive familar with his work, “Patrick is a visionary leader and motivator who also knows when to reshuffle the deck to make things work. Utilizing resources within Connecticut and elsewhere, he has led the company through its clinical trials, FDA approval, and launch of DURLAZA™, a breakthrough pharmaceutical product recently approved by the FDA on a fast-track basis as the first and only prescription low-dose extended-release aspirin for patients with a risk for secondary strokes or acute cardiac events. Patrick has raised a significant amount of capital from a variety of investors and capital providers, and he has hired a talented and deep management team.”

Mr. Fourteau has been a member of the New Haven Pharmaceuticals Board of Directors since 2011. He served as President & CEO of Shionogi US operations from 2008 through August, 2010. From 2003 through 2008, he served as President, CEO, and member of the Board of Directors of Sciele Pharma, Inc., which was acquired by Shionogi & Co., LTD in September, 2008. Previously Patrick served as President of the US operations of inVentiv Health US, Inc. He has also served as President of various divisions of St. Jude Medical, Inc. In addition, he served as an Executive of Eli Lilly and Company, and he is currently a member of the Board of Insys Therapeutics, Inc. Patrick earned his B.A. and M.A. in Mathematics from the University of California, Berkeley and an M.B.A. from Harvard University.